» Articles » PMID: 28488124

Hypomyopathic Dermatomyositis Associated with Interstitial Lung Disease and Good Response to Mycophenolate Mofetil: Case-based Review

Overview
Journal Clin Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2017 May 11
PMID 28488124
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Hypomyopathic dermatomyositis (HDM) is a rare form of dermatomyositis (DM). Interstitial lung disease (ILD) associated with clinically amyopathic DM (CADM-ILD) or hypomyopathic DM (HDM-ILD) is a rare condition with a more unfavorable prognosis than ILD associated with classic DM (CDM-ILD). There is no effective treatment for HDM-ILD. A 62-year-old woman with a 6-month history of chronic polyarthritis and myalgia presented skin lesions characteristic of DM (erythematous lesion on extensor surface of elbows, Gottron's papules, V-neck sign) with no clinical muscle impairment (global muscle strength: grade 5). Muscle enzymes (creatine kinase, lactic dehydrogenase, and aldolase) and electroneuromyography (ENMG) were normal. Computed tomography of the chest revealed ILD. Magnetic resonance imaging and muscle biopsy revealed subclinical muscle impairment. High doses of corticosteroids were used without success. As an alternative, 1500 mg/day of mycophenolate mofetil (MMF) was combined with low doses of prednisone, and the patient demonstrated a good clinical response after 3 months of this combination. Twenty-five months after initiating treatment, ILD remains in remission with the use of MMF and a low dose of prednisone. Therefore, MMF can be a good option for the treatment of HDM-ILD.

Citing Articles

Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease.

Mulcaire-Jones E, Pugashetti J, Oldham J, Khanna D Semin Respir Crit Care Med. 2024; 45(3):435-448.

PMID: 38740369 PMC: 11875204. DOI: 10.1055/s-0044-1786155.


Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review.

Cassone G, Sebastiani M, Vacchi C, Erre G, Salvarani C, Manfredi A Drugs Context. 2021; 10.

PMID: 33505480 PMC: 7813435. DOI: 10.7573/dic.2020-8-8.


Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease.

Scirocco C, Gubbiotti A, Sebastiani A, Sebastiani G Case Rep Rheumatol. 2020; 2020:8145790.

PMID: 33204565 PMC: 7654211. DOI: 10.1155/2020/8145790.


Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Pachman L, Khojah A J Pediatr. 2018; 195:16-27.

PMID: 29576174 PMC: 5881602. DOI: 10.1016/j.jpeds.2017.12.053.

References
1.
Cozzani E, Cinotti E, Felletti R, Pelucco D, Rebora A, Parodi A . Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol. 2013; 35(6):687-92. DOI: 10.3109/08923973.2013.833624. View

2.
Wallace B, Vummidi D, Khanna D . Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016; 28(3):236-45. PMC: 4826478. DOI: 10.1097/BOR.0000000000000270. View

3.
Gil B, Merav L, Pnina L, Chagai G . Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol. 2015; 35(8):2125-2130. DOI: 10.1007/s10067-015-2928-8. View

4.
Gerfaud-Valentin M, Ahmad K, Piegay F, Fabien N, Raphanel B, Cordier J . [Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies]. Rev Mal Respir. 2014; 31(9):849-53. DOI: 10.1016/j.rmr.2014.02.010. View

5.
Swigris J, Olson A, Fischer A, Lynch D, Cosgrove G, Frankel S . Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006; 130(1):30-6. DOI: 10.1378/chest.130.1.30. View